UGT1A1 and liver disorder: Since large inter-individual differences in the glucuronidation of silymarin may confound the assessment of silymarin’s efficacy in humans, we evaluated the relationship between UGT1A1 polymorphism and the metabolism and pharmacokinetics of silymarin in patients with liver disease.